Reported analgesic activity in preclinical kratom literature, with a receptor profile distinct from the dominant alkaloid. A complementary contributor to the blend.
Pain relief,
A precision blend of minor kratom alkaloids, fermented in yeast and formulated for liposomal delivery. The lead alkaloid is held proprietary; the blend sits where the analgesic signal lives, separated from the dominant alkaloids the FDA recommended for scheduling action in July 2025.
Scroll the science
The problem · chronic pain
The non-opioid gap is pain medicine’s deepest unmet need.
More than 50 million Americans live with chronic pain. Opioids still account for over 80,000 US overdose deaths every year, and the field still does not have a credible non-opioid analgesic at the scale the problem demands.
- 50M+
- Americans living with chronic pain
- >80K
- US opioid overdose deaths every year
Prevalence
Mortality
The paradox · kratom
Kratom (Mitragyna speciosa) shows real analgesic activity. The catch is which alkaloids the supply chain concentrates: mitragynine and its conversion product 7-hydroxymitragynine, both carrying an opioid-receptor signature.
In July 2025, the FDA recommended 7-OH for scheduling on opioid-like receptor activity. The supply chain is organized around the wrong molecules.
Like CBD and THC in cannabinoids, kratom splits along its alkaloid composition. The minor kratom alkaloids are the CBD of the plant: cleaner receptor profiles, separated from the dominant ones. Korvane is built on that split.
Follow the split, not the plant. Keep the minor alkaloids that make the analgesia interesting. Leave out the dominant ones that carry the risk.
The formulation · the minor-alkaloid blend
What Korvane carries.
A precision blend of minor kratom alkaloids selected for a multi-target analgesic research profile. The lead alkaloid is held proprietary; the complementary alkaloids are profiled below.
Mu-opioid partial agonist that broadens the blend’s receptor coverage. Profiled in the public kratom-alkaloid literature alongside the rest of the family.
What Korvane does not contain.
- Zero 7-hydroxymitragynineThe concentrated 7-OH products FDA recommended for scheduling action in July 2025, citing opioid-like receptor activity and safety concerns.
- Zero mitragynineThe metabolic precursor 7-OH converts from. Standard kratom extracts are dominated by it.
The delivery · liposomal
Encapsulation that biology recognizes.
Korvane delivers the alkaloid blend in lipid vesicles. Liposomal encapsulation protects actives from first-pass metabolism and improves oral bioavailability. The same delivery logic underpins approved medicines like liposomal doxorubicin and amphotericin B. Established encapsulation, applied to a precision-fermented alkaloid blend.
Program reel
Korvane in motion.
Three minor alkaloids. One blend. The kratom story, retold.
Pain researchers, formulators, and computational chemists working across the kratom-alkaloid family can reach the Korvane science team directly.